<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01913938</url>
  </required_header>
  <id_info>
    <org_study_id>Hemophagocytosis_Ulm</org_study_id>
    <nct_id>NCT01913938</nct_id>
  </id_info>
  <brief_title>Hemophagocytosis in Critically Ill Adult Patients</brief_title>
  <acronym>HCIAP</acronym>
  <official_title>Hemophagocytosis in Critically Ill Adult Patients With Cytopenias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out whether non-responsiveness to therapeutic recombinant
      human granulocyte colony-stimulation factor (rhG-CSF) is associated with hemophagocytosis in
      critically ill adult patients with cytopenias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In children with bi- or pancytopenia, hemophagocytosis is known as life-threatening
      hemophagocytic lymphohistiocytosis (HLH). The purpose of the study is to find out whether
      adult patients with bicytopenia or pancytopenia fulfilling the clinical HLH criteria used in
      children reflect life-threatening hemophagocytosis and whether hemophagocytosis is associated
      with responsiveness to recombinant human granulocyte colony-stimulation factor (rhG-CSF) or
      not.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>responsiveness to recombinant human granulocyte colony-stimulating factor (rhG-CSF)</measure>
    <time_frame>within 7 days</time_frame>
    <description>increase in leukocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>8 clinical HLH criteria</measure>
    <time_frame>7 days</time_frame>
    <description>degree of fulfillment x out of 8 clinical HLH criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>differential blood count, enzymes,biomarkers,immunophenotype</measure>
    <time_frame>7 days</time_frame>
    <description>Differential blood count, lactate dehydrogenase, C reactive protein, fibrinogen, triglycerides, ferritin,liver enzymes, aspartate aminotransferase, soluble cluster of differentiation 25, cytokines, procalcitonin biomarkers,immunophenotype (flow cytometry)</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hemophagocytosis</condition>
  <arm_group>
    <arm_group_label>patients with cytopenias</arm_group_label>
    <description>Patients with sepsis and concomitant cytopenias (leukopenia with thrombocytopenia and anemia) who are routinely treated with rhG-CSF will be followed for reconstitution of peripheral blood cell counts. In cooperation with the Department of Hematology, patients are examined for bone marrow cellularity and hemophagocytosis if G-CSF treatment does not result in leukocyte increase.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, white cells, bone marrow
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with leukopenia who are routinely treated with rhG-CSF
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  critically ill adult patients

          -  leukopenia and thrombocytopenia

          -  rhG-CSF therapy

        Exclusion Criteria:

          -  life expectancy &lt; 24 hours

          -  inclusion in other studies

          -  trauma patients with reanimation on scene or immediately dying on hospital admission

          -  pregnancy

          -  hematologic disorder, malignancy

          -  high dose corticosteroid treatment or chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred E Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manfred E Weiss, MD</last_name>
    <phone>49-731-50060226</phone>
    <email>manfred.weiss@uniklinik-ulm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth M Schneider, PhD</last_name>
    <phone>49-731-50060080</phone>
    <email>marion.schneider@uni-ulm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anaesthesiology, University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred E Weiss, MD</last_name>
      <phone>49 (0)731-500-60226</phone>
      <email>manfred.weiss@uniklinik-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth M Schneider, PhD</last_name>
      <phone>49 (0)731-500-60319</phone>
      <email>marion.schneider@uni-ulm.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine III, Comprehensive Infectious Disease Center, University Hospital Ulm, Germany</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Bommer, MD</last_name>
      <phone>+49 (731) 500-45530</phone>
      <email>Martin.Bommer@uniklinik-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth M Schneider, PhD</last_name>
      <phone>+49 (731) 500-60080</phone>
      <email>marion.schneider@uni-ulm.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Schneider EM, Lorenz I, Müller-Rosenberger M, Steinbach G, Kron M, Janka-Schaub GE. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood. 2002 Oct 15;100(8):2891-8.</citation>
    <PMID>12351400</PMID>
  </reference>
  <reference>
    <citation>Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31.</citation>
    <PMID>16937360</PMID>
  </reference>
  <results_reference>
    <citation>Weiss M, Nass M, Schneider EM. Hemophagocytic and/or macrophage activation syndromes may explain thrombocytopenia, leukopenia and anemia in critically ill postoperative/posttraumatic patients. Infection, vol. 39 Suppl. II September, no., pp. S118, 2011.</citation>
  </results_reference>
  <results_reference>
    <citation>Lorenz MR, Walther P, Weiss M, Huber-Lang M, Schneider EM. Autophagy as a unique biosignature in hemophagocytic cells of patients after major trauma. Infection, vol. 37 (Suppl. III), no. P111, pp. S28 - 29, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Schneider EM, Flacke S, Liu F, Lorenz MR, Schilling P, Nass ME, Foehr KJ, Huber-Lang M, Weiss ME. Autophagy and ATP-induced anti-apoptosis in antigen presenting cells (APC) follows the cytokine storm in patients after major trauma. J Cell Commun Signal. 2011 Jun;5(2):145-56. doi: 10.1007/s12079-010-0113-z. Epub 2011 Jan 13.</citation>
    <PMID>21484192</PMID>
  </results_reference>
  <results_reference>
    <citation>Weiss M, Bommer M, Hohmann H, Walther P, Schneider EM. The clinical definition of hemophagocytic lymphohistiocytosis (HLH) as used in children does not explain cytopenia in the majority of critically ill postoperative/posttraumatic patients. Infection 41 Suppl 1: S43 - S44, 2013. DOI 10.1007/s15010-013-0513-0</citation>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2013</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Manfred Weiss</investigator_full_name>
    <investigator_title>Professor, MD, MBA</investigator_title>
  </responsible_party>
  <keyword>Hemophagocytosis, adults, rhG-CSF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

